Skip to main content
Top
Published in: Endocrine 2/2017

01-08-2017 | Original Article

Natural history of graves’ orbitopathy after treatment

Authors: Francesca Menconi, Marenza Leo, Elena Sabini, Teresa Mautone, Marco Nardi, Aldo Sainato, Stefano Sellari-Franceschini, Paolo Vitti, Claudio Marcocci, Michele Marinò

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

Intravenous glucocorticoids are used for Graves’ orbitopathy, alone or associated with/followed by additional treatments (orbital radiotherapy, orbital decompression, palpebral or eye surgery). However, the relation between associated/additional treatments and other variables with Graves’ orbitopathy outcome following intravenous glucocorticoids is not clear. Thus, the present study was conducted to investigate retrospectively the impact of associated/additional treatments and other variables on Graves’ orbitopathy outcome after intravenous glucocorticoids. We evaluated 226 untreated Graves’ orbitopathy patients. Following first observation, patients were given intravenous glucocorticoids and re-examined after a median of 46.5 months. The end-points were the relation between Graves’ orbitopathy outcome, outcome of NOSPECS score and of the single Graves’ orbitopathy features with several variables, including associated/additional treatments. All Graves’ orbitopathy features improved significantly after treatment. Overall, Graves’ orbitopathy improved in ~60 % of patients (responders), whereas it was stable or worsened in ~40 % of patients (non-responders). Time between first and last observation and clinical activity score at first observation correlated significantly with Graves’ orbitopathy outcome. The outcomes of NOSPECS, eyelid aperture, clinical activity score and diplopia correlated with time between the first and last observation. The NOSPECS outcome correlated with gender. The outcomes of proptosis, eyelid aperture and visual acuity correlated with orbital decompression. The outcome of diplopia correlated with orbital radiotherapy. Taking into account the limitations of retrospective investigations, our findings confirm that time (i.e. the natural history of Graves’ orbitopathy) is a key factor in determining the long-term outcome of Graves’ orbitopathy, radiotherapy is effective for diplopia, and orbital decompression is followed by an amelioration of several Graves’ orbitopathy features.
Literature
1.
go back to reference L. Bartalena, L. Baldeschi, K. Boboridis, A. Eckstein, G.J. Kahaly, C. Marcocci, P. Perros, M. Salvi, W.M. Wiersinga; European Group on Graves’ Orbitopathy (EUGOGO), The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016)CrossRefPubMedPubMedCentral L. Bartalena, L. Baldeschi, K. Boboridis, A. Eckstein, G.J. Kahaly, C. Marcocci, P. Perros, M. Salvi, W.M. Wiersinga; European Group on Graves’ Orbitopathy (EUGOGO), The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016)CrossRefPubMedPubMedCentral
2.
go back to reference L. Bartalena, A. Pinchera, C. Marcocci, Management of Graves’ ophthalmopathy: reality and perspectives. Endocr. Rev. 212, 168–199 (2000) L. Bartalena, A. Pinchera, C. Marcocci, Management of Graves’ ophthalmopathy: reality and perspectives. Endocr. Rev. 212, 168–199 (2000)
3.
go back to reference C. Marcocci, M. Marinò, Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 325–337 (2012)CrossRefPubMed C. Marcocci, M. Marinò, Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 325–337 (2012)CrossRefPubMed
4.
go back to reference C. Marcocci, A. Pinchera, M. Marinò, A treatment strategy for Graves’ orbitopathy. Nat. Clin. Pract. Endocrinol. Metab. 3, 430–436 (2007)CrossRefPubMed C. Marcocci, A. Pinchera, M. Marinò, A treatment strategy for Graves’ orbitopathy. Nat. Clin. Pract. Endocrinol. Metab. 3, 430–436 (2007)CrossRefPubMed
5.
go back to reference A.K. Eckstein, M. Plicht, H. Lax, M. Neuhäuser, K. Mann, S. Lederbogen, C. Heckmann, J. Esser, N.G. Morgenthaler, Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91, 3464–3470 (2006)CrossRefPubMed A.K. Eckstein, M. Plicht, H. Lax, M. Neuhäuser, K. Mann, S. Lederbogen, C. Heckmann, J. Esser, N.G. Morgenthaler, Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91, 3464–3470 (2006)CrossRefPubMed
6.
go back to reference W.M. Wiersinga, Smoking and thyroid. Clin. Endocrinol. (Oxf) 79, 145–151 (2013)CrossRef W.M. Wiersinga, Smoking and thyroid. Clin. Endocrinol. (Oxf) 79, 145–151 (2013)CrossRef
7.
go back to reference F. Menconi, M. Marinò, A. Pinchera, R. Rocchi, B. Mazzi, M. Nardi, L. Bartalena, C. Marcocci, Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J. Clin. Endocrinol. Metab. 92, 1653–1658 (2007)CrossRefPubMed F. Menconi, M. Marinò, A. Pinchera, R. Rocchi, B. Mazzi, M. Nardi, L. Bartalena, C. Marcocci, Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J. Clin. Endocrinol. Metab. 92, 1653–1658 (2007)CrossRefPubMed
8.
go back to reference M. Leo, C. Marcocci, A. Pinchera, M. Nardi, L. Megna, R. Rocchi, F. Latrofa, M.A. Altea, B. Mazzi, E. Sisti, M.A. Profilo, M. Marinò, Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial. J. Clin. Endocrinol. Metab. 97, E44–E48 (2012)CrossRefPubMed M. Leo, C. Marcocci, A. Pinchera, M. Nardi, L. Megna, R. Rocchi, F. Latrofa, M.A. Altea, B. Mazzi, E. Sisti, M.A. Profilo, M. Marinò, Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial. J. Clin. Endocrinol. Metab. 97, E44–E48 (2012)CrossRefPubMed
9.
go back to reference F. Menconi, M. Leo, P. Vitti, C. Marcocci, M. Marinò, Total thyroid ablation in Graves’ orbitopathy. J. Endocrinol. Invest. 38, 809–815 (2015)CrossRefPubMed F. Menconi, M. Leo, P. Vitti, C. Marcocci, M. Marinò, Total thyroid ablation in Graves’ orbitopathy. J. Endocrinol. Invest. 38, 809–815 (2015)CrossRefPubMed
11.
go back to reference F. Menconi, M.A. Profilo, M. Leo, E. Sisti, M.A. Altea, R. Rocchi, F. Latrofa, M. Nardi, P. Vitti, C. Marcocci, M. Marinò, Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid 24, 60–66 (2014)CrossRefPubMedPubMedCentral F. Menconi, M.A. Profilo, M. Leo, E. Sisti, M.A. Altea, R. Rocchi, F. Latrofa, M. Nardi, P. Vitti, C. Marcocci, M. Marinò, Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid 24, 60–66 (2014)CrossRefPubMedPubMedCentral
12.
go back to reference E. Sisti, F. Menconi, M. Leo, M.A. Profilo, T. Mautone, B. Mazzi, R. Rocchi, F. Latrofa, M. Nardi, P. Vitti, C. Marcocci, M. Marinò, Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J. Endocrinol. Invest. 38, 661–668 (2015)CrossRefPubMed E. Sisti, F. Menconi, M. Leo, M.A. Profilo, T. Mautone, B. Mazzi, R. Rocchi, F. Latrofa, M. Nardi, P. Vitti, C. Marcocci, M. Marinò, Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J. Endocrinol. Invest. 38, 661–668 (2015)CrossRefPubMed
13.
go back to reference M. Leo, T. Mautone, I. Ionni, M.A. Profilo, E. Sabini, F. Menconi, B. Mazzi, R. Rocchi, F. Latrofa, M. Nardi, P. Vitti, C. Marcocci, M. Marinò, Variables affecting the long term outcome of Graves’ orbitopathy following high dose intravenous glucocorticoid pulse therapy in patients not treated with orbital radiotherapy. Endoc. Pract. [in press] M. Leo, T. Mautone, I. Ionni, M.A. Profilo, E. Sabini, F. Menconi, B. Mazzi, R. Rocchi, F. Latrofa, M. Nardi, P. Vitti, C. Marcocci, M. Marinò, Variables affecting the long term outcome of Graves’ orbitopathy following high dose intravenous glucocorticoid pulse therapy in patients not treated with orbital radiotherapy. Endoc. Pract. [in press]
14.
go back to reference L. Bartalena, C. Marcocci, L. Chiovato, M. Laddaga, G. Lepri, D. Andreani, G. Cavallacci, L. Baschieri, A. Pinchera, Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J. Clin. Endocrinol. Metab. 56, 1139–1144 (1983)CrossRefPubMed L. Bartalena, C. Marcocci, L. Chiovato, M. Laddaga, G. Lepri, D. Andreani, G. Cavallacci, L. Baschieri, A. Pinchera, Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J. Clin. Endocrinol. Metab. 56, 1139–1144 (1983)CrossRefPubMed
15.
go back to reference C. Marcocci, L. Bartalena, F. Bogazzi, G. Bruno-Bossio, A. Lepri, A. Pinchera, Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J. Endocrinol. Invest. 14, 853–860 (1991)CrossRefPubMed C. Marcocci, L. Bartalena, F. Bogazzi, G. Bruno-Bossio, A. Lepri, A. Pinchera, Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J. Endocrinol. Invest. 14, 853–860 (1991)CrossRefPubMed
16.
go back to reference M.P. Mourits, M.F. Prummel, W.M. Wiersinga, L. Koornneef, Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf) 47, 9–14 (1997)CrossRef M.P. Mourits, M.F. Prummel, W.M. Wiersinga, L. Koornneef, Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf) 47, 9–14 (1997)CrossRef
17.
go back to reference L. Bartalena, L. Baldeschi, A.J. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M.P. Mourits, P. Perros, K. Boboridis, A. Boschi, N. Currò, C. Daumerie, G.J. Kahaly, G. Krassas, C.M. Lane, J.H. Lazarus, M. Marinò, M. Nardi, C. Neoh, J. Orgiazzi, S. Pearce, A. Pinchera, S. Pitz, M. Salvi, P. Sivelli, M. Stahl, G. von Arx, W.M. Wiersinga, Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 18, 333–346 (2008)CrossRefPubMed L. Bartalena, L. Baldeschi, A.J. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M.P. Mourits, P. Perros, K. Boboridis, A. Boschi, N. Currò, C. Daumerie, G.J. Kahaly, G. Krassas, C.M. Lane, J.H. Lazarus, M. Marinò, M. Nardi, C. Neoh, J. Orgiazzi, S. Pearce, A. Pinchera, S. Pitz, M. Salvi, P. Sivelli, M. Stahl, G. von Arx, W.M. Wiersinga, Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 18, 333–346 (2008)CrossRefPubMed
18.
go back to reference W.M. Wiersinga, P. Perros, G.J. Kahaly, M.P. Mourits, L. Baldeschi, K. Boboridis, A. Boschi, A.J. Dickinson, P. Kendall-Taylor, G.E. Krassas, C.M. Lane, J.H. Lazarus, C. Marcocci, M. Marino, M. Nardi, C. Neoh, J. Orgiazzi, A. Pinchera, S. Pitz, M.F. Prummel, M.S. Sartini, M. Stahl, G. von Arx, Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur. J. Endocrinol. 155, 387–389 (2006)CrossRefPubMed W.M. Wiersinga, P. Perros, G.J. Kahaly, M.P. Mourits, L. Baldeschi, K. Boboridis, A. Boschi, A.J. Dickinson, P. Kendall-Taylor, G.E. Krassas, C.M. Lane, J.H. Lazarus, C. Marcocci, M. Marino, M. Nardi, C. Neoh, J. Orgiazzi, A. Pinchera, S. Pitz, M.F. Prummel, M.S. Sartini, M. Stahl, G. von Arx, Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur. J. Endocrinol. 155, 387–389 (2006)CrossRefPubMed
19.
go back to reference M.A. Profilo, E. Sisti, C. Marcocci, P. Vitti, A. Pinchera, M. Nardi, R. Rocchi, F. Latrofa, F. Menconi, M.A. Altea, M. Leo, T. Rago, M. Marinò, Thyroid volume and severity of Graves’ orbitopathy. J. Endocrinol. Invest. 23, 97–102 (2013) M.A. Profilo, E. Sisti, C. Marcocci, P. Vitti, A. Pinchera, M. Nardi, R. Rocchi, F. Latrofa, F. Menconi, M.A. Altea, M. Leo, T. Rago, M. Marinò, Thyroid volume and severity of Graves’ orbitopathy. J. Endocrinol. Invest. 23, 97–102 (2013)
20.
go back to reference S.C. Werner, Modification of the classification of the eye changes of Graves’ disease: recommendations of the Ad Hoc committee of the American thyroid association. J. Clin. Endocrinol. Metab. 44, 203–204 (1977)CrossRefPubMed S.C. Werner, Modification of the classification of the eye changes of Graves’ disease: recommendations of the Ad Hoc committee of the American thyroid association. J. Clin. Endocrinol. Metab. 44, 203–204 (1977)CrossRefPubMed
21.
go back to reference S. Zang, K.A. Ponto, G.J. Kahaly, Clinical review: Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J. Clin. Endocrinol. Metab. 96, 320–332 (2011)CrossRefPubMed S. Zang, K.A. Ponto, G.J. Kahaly, Clinical review: Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J. Clin. Endocrinol. Metab. 96, 320–332 (2011)CrossRefPubMed
22.
go back to reference R. Rocchi, R. Lenzi, M. Marinò, F. Latrofa, M. Nardi, P. Piaggi, B. Mazzi, M.A. Altea, A. Pinchera, P. Vitti, C. Marcocci, S. Sellari-Franceschini, Rehabilitative orbital decompression for Graves’ orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients’ satisfaction. Thyroid 22, 1170–1175 (2012)CrossRefPubMed R. Rocchi, R. Lenzi, M. Marinò, F. Latrofa, M. Nardi, P. Piaggi, B. Mazzi, M.A. Altea, A. Pinchera, P. Vitti, C. Marcocci, S. Sellari-Franceschini, Rehabilitative orbital decompression for Graves’ orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients’ satisfaction. Thyroid 22, 1170–1175 (2012)CrossRefPubMed
23.
go back to reference C. Marcocci, M. Marinò, R. Rocchi, F. Menconi, E. Morabito, A. Pinchera, Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy. J. Endocrinol. Invest. 27, 272–280 (2004)CrossRefPubMed C. Marcocci, M. Marinò, R. Rocchi, F. Menconi, E. Morabito, A. Pinchera, Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy. J. Endocrinol. Invest. 27, 272–280 (2004)CrossRefPubMed
24.
go back to reference M. Moleti, M.A. Violi, D. Montanini, C. Trombetta, B. Di Bella, G. Sturniolo, S. Presti, A. Alibrandi, A. Campennì, S. Baldari, F. Trimarchi, F. Vermiglio, Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves’ orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J. Clin. Endocrinol. Metab. 99, 1783–1789 (2014)CrossRefPubMed M. Moleti, M.A. Violi, D. Montanini, C. Trombetta, B. Di Bella, G. Sturniolo, S. Presti, A. Alibrandi, A. Campennì, S. Baldari, F. Trimarchi, F. Vermiglio, Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves’ orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J. Clin. Endocrinol. Metab. 99, 1783–1789 (2014)CrossRefPubMed
Metadata
Title
Natural history of graves’ orbitopathy after treatment
Authors
Francesca Menconi
Marenza Leo
Elena Sabini
Teresa Mautone
Marco Nardi
Aldo Sainato
Stefano Sellari-Franceschini
Paolo Vitti
Claudio Marcocci
Michele Marinò
Publication date
01-08-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1136-x

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.